Antithrombin Dublin (p.Val30Glu): A relatively common variant with moderate thrombosis risk of causing transient antithrombin deficiency

Thrombosis and Haemostasis

Volumn 116, Issue 1, 2016, Pages 146-154

  Navarro Fernández, José ^a   De La Morena Barrio, María Eugenia ^a   Padilla, José ^a   Miñano, Antonia ^a   Bohdan, Nataliya ^a   Águila, Sonia ^a   Martínez Martínez, Irene ^a   Sevivas, Teresa S ^b   De Cos, Carmen ^c   Fernández Mosteirín, Nuria ^d   Llamas, Pilar ^e   Asenjo, Susana ^f   Medina, Pilar ^g   Souto, Carlos ^h   Overvad, Kim ^i,j   Kristensen, Søren R ⁱ   Corral, Javier ^a   Vicente, Vicente ^a  

^a HOSPITAL UNIVERSITARIO MORALES MESEGUER   (Spain)

^b CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^c HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^d HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^e Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^f HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^g INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^h HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

ⁱ AALBORG UNIVERSITY HOSPITAL   (Denmark)

^j AARHUS UNIVERSITY   (Denmark)

more..

Author keywords

Antithrombin; Deficiency; Polymorphism; SERPINC1; Thrombophilia

Indexed keywords

ANTIGEN; ANTITHROMBIN DUBLIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5 LEIDEN; DNA; EPSTEIN BARR VIRUS ANTIGEN; HUMAN EMBRYONIC KIDNEY EPSTEIN BARR VIRUS ANTIGEN; PROTEINASE; RECOMBINANT ANTITHROMBIN III; UNCLASSIFIED DRUG; ANTITHROMBIN III DUBLIN; RECOMBINANT PROTEIN; SIGNAL PEPTIDE;

ADULT; AGED; ANTITHROMBIN DEFICIENCY; ARTICLE; CALORIMETRY; CASE CONTROL STUDY; CONTROLLED STUDY; DOWN SYNDROME; EDMAN SEQUENCING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MIDDLE AGED; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; RISK FACTOR; SEQUENCE ANALYSIS; VEIN THROMBOSIS; AMINO ACID SUBSTITUTION; BLOOD; CHEMISTRY; COMPLICATION; GENETICS; HEK293 CELL LINE; HETEROZYGOTE; MALE; METABOLISM; MISSENSE MUTATION; THROMBOSIS;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANTITHROMBIN III; ANTITHROMBIN III DEFICIENCY; CASE-CONTROL STUDIES; FEMALE; HEK293 CELLS; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PROTEIN SORTING SIGNALS; RECOMBINANT PROTEINS; RISK FACTORS; THROMBOSIS;

EID: 84977521046     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-11-0871     Document Type: Article

References (42)

1. Olds RJ, Lane DA, Mille B, et al. Antithrombin: the principal inhibitor of thrombin. Semin Thromb Haemost 1994; 20: 353-372.
2. Ishiguro K, Kojima T, Kadomatsu K, et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest 2000; 106: 873-878.
3. Liu Y, Kretz CA, Maeder ML, et al. Targeted mutagenesis of zebrafish antithrombin III triggers disseminated intravascular coagulation and thrombosis, revealing insight into function. Blood 2014; 124: 142-150.
4. Bucciarelli P, Passamonti SM, Biguzzi E, et al. Low borderline plasma levels of antithrombin, protein C and protein S are risk factors for venous thromboembolism. J Thromb Haemost 2012; 10: 1783-1791.
5. Di Minno MN, Dentali F, Veglia F, et al. Antithrombin levels and the risk of a first episode of venous thromboembolism: a case-control study. Thromb Haemost 2013; 109: 167-169.
6. Egeberg O. On the natural blood coagulation inhibitor system. Investigations of inhibitor factors based on antithrombin deficient blood. Thromb Diath Haemorrh 1965; 14: 473-489.
7. Martinelli I, De Stefano V, Mannucci PM. Inherited risk factors for venous thromboembolism. Nat Rev Cardiol 2014; 11: 140-156.
8. Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism-- results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997; 77: 444-451.
9. Kristensen SR, Rasmussen B, Pedersen S, et al. Detecting antithrombin deficiency may be a difficult task--more than one test is necessary. J Thromb Haemost 2007; 5: 617-618.
10. Ungerstedt JS, Schulman S, Egberg N, et al. Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: do factor Xa-based methods overestimate antithrombin activity in some patients? Blood 2002; 99: 2271-2272.
11. Cooper PC, Coath F, Daly ME, et al. The phenotypic and genetic assessment of antithrombin deficiency. Int J Lab Hematol 2011; 33: 227-237.
12. Javela K, Engelbarth S, Hiltunen L, et al. Great discrepancy in antithrombin activity measured using five commercially available functional assays. Thromb Res 2013; 132: 132-137.
13. Moore GW, de Jager N, Cutler JA. Development of a novel, rapid assay for detection of heparin-binding defect antithrombin deficiencies: the heparin-antithrombin binding (HAB) ratio. Thromb Res 2015; 135: 161-166.
14. Vinazzer H. Hereditary and acquired antithrombin deficiency. Semin Thromb Haemost 1999; 25: 257-263.
15. Kottke-Marchant K, Duncan A. Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med 2002; 126: 1326-1336.
16. Muszbek L, Bereczky Z, Kovacs B, et al. Antithrombin deficiency and its laboratory diagnosis. Clin Chem Lab Med 2010; 48 (Suppl 1): S67-S78.
17. Corral J, González-Conejero R, Soria JM, et al. A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. Blood 2006; 108: 177-183.
18. Severinsen MT, Overvad K, Johnsen SP, et al. Genetic susceptibility, smoking, obesity and risk of venous thromboembolism. Br J Haematol 2010; 149: 273-279.
19. de la Morena-Barrio ME, Antón AI, Martínez-Martínez I, et al. Regulatory regions of SERPINC1 gene: identification of the first mutation associated with antithrombin deficiency. Thromb Haemost 2012; 107: 430-437.
20. Corral J, Huntington JA, González-Conejero R, et al. Mutations in the shutter region of antithrombin result in formation of disulfide-linked dimers and severe venous thrombosis. J Thromb Haemost 2004; 2: 931-939.
21. Martínez-Martínez I, Ordóñez A, Navarro-Fernández J, et al. Antithrombin Murcia (K241E) causing antithrombin deficiency: a possible role for altered glycosylation. Haematologica 2010; 95: 1358-1365.
22. Martínez-Martínez I, Johnson DJ, Yamasaki M, et al. Type II antithrombin deficiency caused by a large in-frame insertion: structural, functional and pathological relevance. J Thromb Haemost 2012; 10: 1859-1866.
23. Daly M, O’Meara A, Hallinan FM. Identification and characterisation of a new antithrombin III familial variant (AT Dublin) with possible increased frequency in children with cancer. Br J Haematol 1987; 65: 457-462.
24. Thein SL, Lane DA. Use of synthetic oligonucleotides in the characterisation of antithrombin III Northwick Park (393 CGT----TGT) and antithrombin III Glasgow (393 CGT----CAT). Blood 1988; 72: 1817-1821.
25. Picard V, Bura A, Emmerich J, et al. Molecular bases of antithrombin deficiency in French families: identification of seven novel mutations in the antithrombin gene. Br J Haematol 2000; 110: 731-734.
26. Pavlova A, El-Maarri O, Luxembourg B, et al. Detection of heterozygous large deletions in the antithrombin gene using multiplex polymerase chain reaction and denatured high performance liquid chromatography. Haematologica 2006; 91: 1264-1267.
27. Daly M, Bruce D, Perry DJ, et al. Antithrombin Dublin (-3 Val----Glu): an N-terminal variant which has an aberrant signal peptidase cleavage site. FEBS Lett 1990; 273: 87-90.
28. Simioni P, Tormene D, Tognin G, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 2009; 361: 1671-1675.
29. Miyawaki Y, Suzuki A, Fujita J, et al. Thrombosis from a prothrombin mutation conveying antithrombin resistance. N Engl J Med 2012; 366: 2390-2396.
30. Millar DS, Lopez A, White D, et al. Screening for mutations in the antithrombin III (AT3) gene causing recurrent venous thrombosis by single strand conformation polymorphism analysis. Human Mutation 1993; 2: 324-326.
31. Puurunen M, Salo P, Engelbarth S, et al. Type II antithrombin deficiency caused by a founder mutation Pro73Leu in the Finnish population: clinical picture. J Thromb Haemost 2013; 11: 1844-1849.
32. Germain M, Chasman DI, de Haan H, et al. Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism. Am J Hum Genet 2015; 96: 532-542.
33. Luxembourg B, Delev D, Geisen C, et al. Molecular basis of antithrombin deficiency. Thromb Haemost 2011; 105: 635-646.
34. Caspers M, Pavlova A, Driesen J, et al. Deficiencies of antithrombin, protein C and protein S - practical experience in genetic analysis of a large patient cohort. Thromb Haemost 2012; 108: 247-257.
35. Corral J, Vicente V, Carrell RW. Thrombosis as a conformational disease. Haematologica 2005; 90: 238-246.
36. Mushunje A, Evans G, Brennan SO, et al. Latent antithrombin and its detection, formation and turnover in the circulation. J Thromb Haemost 2004; 2: 2170-2177.
37. Corral J, Rivera J, Guerrero JA, et al. Latent and polymeric antithrombin: clearance and potential thrombotic risk. Exp Biol Med 2007; 232: 219-226.
38. Bruce D, Perry DJ, Borg JY, et al. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn-->Asp). J Clin Invest 1994; 94: 2265-2274.
39. Beauchamp NJ, Pike RN, Daly M, et al. Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation. Blood 1998; 92: 2696-2706.
40. Zhang Q, Buckle AM, Law RH, et al. The N terminus of the serpin, tengpin, functions to trap the metastable native state. EMBO Rep 2007; 8: 658-663.
41. Corral J, Vicente V. Puzzling questions on antithrombin: Diagnostic limitations and real incidence in venous and arterial thrombosis. Thromb Res 2015; 135: 1047-1048.
42. Fischer R, Sachs UJ, Heidinger KS, et al. Prevalence of hereditary antithrombin mutations is higher than estimated in patients with thrombotic events. Blood Coagul Fibrinolysis 2013; 24: 444-448.